Author Archives: Bruno Quinney

Professor Glenn King working in the lab with a funnel web spider. Credit The University of Queensland
#Australia #Heart attack #Stroke #University of Queensland

Spider venom peptide trialled as cardiovascular treatment 

A potential treatment for heart attack and stroke derived from spider venom has been administered to the first participants in clinical trial.  A team of researchers from the University of Queensland, Australia published preclinical analysis showing the protein Hi1a could treat heart attack and stroke patients. The… Read More

#News

Neurodegenerative disorders
#Financing #Metabolic diseases #Neurodegenerative disorders #Novel therapeutics

Soley Therapeutics raises $200m to advance oncology leads 

Biotechnology company Soley Therapeutics has raised $200 million Series C financing to advance its proprietary cell stress sensing platform and pipeline of novel therapeutics into clinic.  It is believed Soley intends to use the funds to support its work filing investigational new drug (IND) applications and its… Read More

#Business & Investment #News

#Breast cancer #Cell therapy #Clinical trial #GLP-1 #Huntington's disease #LoQus23 Therapeutics #Metabolic diseases #Obesity #Osteoarthritis #Ozempic #Phesi #RNAi #Scarcell Therapeutics #Weight loss

This week in Drug Discovery (5 – 9 January) 

News round-up for 5 – 9 January by Bruno Quinney, Content Team at DDW.  This week in DDW, a new report finds breast cancer is the world’s most studied disease for the fifth year running. That same report predicts obesity to break into the top five, with weight loss a key theme across… Read More

#News

#AI #Bayer #Cradle #Drug discovery

Bayer partners with Cradle to advance AI-led drug discovery 

Pharma giant Bayer has signed a three-year strategic collaboration with biotech company Cradle to advance AI-enabled antibody discovery and optimisation.  Bayer aims to implement Cradle’s AI software platform, used for protein engineering, to scale its drug discovery and development efforts. The company intends to integrate Cradle’s platform… Read More

#Business & Investment #News

#AbbVie #Funding #Pioneer Group

They’ve got a Golden Ticket: Alceus Bio wins 2025 initiative 

Biotechnology company Alceus Bio has been awarded Pioneer Group and AbbVie’s 2025 Golden Ticket.  The company, a developer of synthetic chimeric antigen receptor T-lymphocyte therapies for solid malignancies, was chosen as the winner after an extensive selection process.  The Golden Ticket provides a significant package of… Read More

#News

#Biopharma #Evaluate Pharma #Merck #Mergers and acquisitions #Oncology

M&A boosted biopharma by $36bn at end of 2025, report finds 

A surge in mergers and acquisitions (M&A) boosted the biopharma market by $36 billion at the end of 2025, a new report finds.  Evaluate’s 2026 Preview Report shows $36 billion was generated through M&A last October and November, largely through biotech buyout. The report predicts M&A will continue to play an… Read More

#Business & Investment #News

#AI #Heart disease #Lung disease #Qureight

Qureight appoints Dr Steven Bishop as CMO 

Techbio company Qureight has announced the appointment of Dr Steven Bishop as Chief Medical Officer.  Bishop previously served as Chief Data Officer for the company, which uses AI-powered CT imaging biomarkers and its clinical data management platform to advance understanding of lung and heart diseases.  As CMO, Bishop… Read More

#News

CAR-T cell therapy
#Advanced Therapies #CAR-T #Clinical trial #Financing

Vyriad raises $85m to advance CAR-T candidate to clinic 

Biotechnology company Vyriad has closed the final $25 million tranche of its Series B financing round to advance the company’s in vivo CAR-T candidate to clinic.  VV169 has been developed by Vyriad for the treatment of patients with relapsed or treatment-refractory multiple myeloma. The treatment is one of the first in… Read More

#Business & Investment #News

#AstraZeneca #Clinical trial #Lupus

AstraZeneca’s lupus treatment shows positive results 

AstraZeneca’s Saphnelo (anifrolumab) has demonstrated strong results for the treatment of systemic lupus erythematosus (SLE).  In the Phase III TULIP-SC trial, 56.2% of patients who received Saphnelo via subcutaneous (SC) self-administration achieved a reduction in disease activity at Week 52 versus 37.1% receiving placebo, as measured by the British Isles Lupus Assessment Group-based Composite Lupus… Read More

#News

Neuronal inclusions in Huntington’s disease
#Biotech #Huntington's disease #LoQus23 Therapeutics

Groundbreaking Huntington’s disease drug set for development 

Biotechnology company LoQus23 Therapeutics has nominated its drug candidate LQT-23 for development as a treatment for Huntington’s Disease (HD).  LQT-23 is a first-in-class oral drug candidate which has shown potential to slow or stop the progression of HD. The candidate works as an allosteric small molecule inhibitor… Read More

#News

#GLP-1 #Ozempic #UCL #Weight loss

1.6 million UK patients used weight loss drugs in past year 

An estimated 1.6 million adults in England, Wales and Scotland used weight loss drugs in the past year, new findings suggest.  The study, led by researchers at University College London, showed 1.6 million adults used drugs including Wegovy and Mounjaro to help lose weight between early 2024 and early 2025. Read More

#News

#Biosciences #Fujifilm #Life sciences

FUJIFILM Irvine Scientific announces rebrand 

FUJIFILM Irvine Scientific has rebranded as FUJIFILM Biosciences, a decision the company hopes will build on FUJIFILM’s work in the life science industry.  FUJIFILM Biosciences has pledged to continue its customer-focus, empowering scientists and researchers at every stage of discovery, development, and commercialisation. By offering a products and services… Read More

#Business & Investment #News

Asthma inhaler
#Asthma #Clinical trial

Apogee to advance potential best-in-class asthma treatment 

Biotechnology company Apogee Therapeutics has shared positive data for its potential best-in-class treatment for mild-to-moderate asthma.  Zumilokibart (APG77) was assessed in a Phase Ib double-blind, placebo-controlled trial of 19 adult patients with mild-to-moderate asthma. Results show the treatment was well-tolerated and offered a robust and durable suppression of FeNO, a biomarker… Read More

#News

Weight loss concept
#Metabolic diseases #Obesity #RNAi

RNAi-based therapeutics could treat obesity, results show 

A new approach to treating obesity and metabolic diseases has shown promising early results in Phase I/IIa clinical trials.  ARO-INHBE and ARO-ALK7 are investigational RNA interference (RNAi) therapeutics, developed by biotechnology company Arrowhead Pharmaceuticals. Preliminary results in Phase I/IIa trials found meaningful reductions in visceral fat, total fat and liver fat, suggesting… Read More

#News

#Clarivate #Drug discovery

Clarivate’s Drugs to Watch could ‘transform care’ 

Analytics company Clarivate has released its 2026 Drugs to Watch report, with eleven therapies expected to deliver clinical and commercial impact this coming year.  The annual analysis highlights therapies expected to reshape treatment approaches across metabolic disease, oncology, immunology, rare conditions and neurological disorders, with the potential to achieve… Read More

#News